ATE334993T1 - Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents

Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten

Info

Publication number: ATE334993T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; alendronate; production; sodium salt; compositions containing
Prior art date: 1998-08-27

Application number

AT99944004T

Other languages

English (en)

Inventor

Nina Finkelstein

Ramy Lidor-Hadas

Judith Aronhime

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-27

Publication date

2006-08-15

1999-08-27 Application filed by Teva Pharma filed Critical Teva Pharma

2006-08-15 Application granted granted Critical

2006-08-15 Publication of ATE334993T1 publication Critical patent/ATE334993T1/de

Links

OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title abstract 4
238000004519 manufacturing process Methods 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
229940062527 alendronate Drugs 0.000 title 1
NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 title 1
229960004343 alendronic acid Drugs 0.000 abstract 3
208000006386 Bone Resorption Diseases 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
238000010348 incorporation Methods 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT99944004T 1998-08-27 1999-08-27 Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten ATE334993T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US9831398P	1998-08-27	1998-08-27
US12974399P	1999-04-16	1999-04-16
US14446199P	1999-07-19	1999-07-19

Publications (1)

Publication Number	Publication Date
ATE334993T1 true ATE334993T1 (de)	2006-08-15

Family

ID=27378576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99944004T ATE334993T1 (de)	1998-08-27	1999-08-27	Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten

Country Status (30)

Country	Link
US (2)	US6281381B1 (de)
EP (1)	EP1107974B1 (de)
JP (2)	JP2002523514A (de)
KR (2)	KR20070034132A (de)
AT (1)	ATE334993T1 (de)
AU (1)	AU5698899A (de)
BG (1)	BG65329B1 (de)
BR (1)	BR9913472A (de)
CA (1)	CA2341459A1 (de)
CZ (1)	CZ2001629A3 (de)
DE (1)	DE69932620T2 (de)
DK (1)	DK1107974T3 (de)
EA (1)	EA002739B1 (de)
EE (1)	EE04552B1 (de)
ES (1)	ES2270613T3 (de)
HR (1)	HRP20010129A2 (de)
HU (1)	HUP0203078A3 (de)
IL (1)	IL141423A (de)
IS (1)	IS5864A (de)
LT (1)	LT4888B (de)
LV (1)	LV12720B (de)
NO (1)	NO20010957L (de)
NZ (1)	NZ510682A (de)
PL (1)	PL346347A1 (de)
PT (1)	PT1107974E (de)
RO (1)	RO122854B1 (de)
SI (1)	SI20581B (de)
SK (1)	SK2482001A3 (de)
WO (1)	WO2000012517A1 (de)
YU (1)	YU14701A (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2451881A1 (fr) *	2001-07-16	2003-01-30	Universite Paris 13	Nouveaux derives de bisphosphonates, leurs preparations et utilisations
GB2383042A (en) *	2001-10-18	2003-06-18	Cipla Ltd	Amorphous alendronate sodium
US20040052843A1 (en) *	2001-12-24	2004-03-18	Lerner E. Itzhak	Controlled release dosage forms
NZ552514A (en) *	2001-12-24	2008-08-29	Teva Pharma	Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) *	2002-01-29	2003-07-29	Lyogen Ltd	Alendronato monosodico amorfo e processo per la sua preparazione
AU2003226148A1 (en) *	2002-04-05	2003-10-27	Merck & Co., Inc.	Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) *	2002-09-05	2008-10-09	Deluca Hector F	Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) *	2003-10-14	2005-05-26	Pliva - Research And Development Ltd.	Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) *	2004-02-12	2005-08-18	Indranil Nandi	Alendronate salt tablet compositions
US20050261250A1 (en) *	2004-05-19	2005-11-24	Merck & Co., Inc.,	Compositions and methods for inhibiting bone resorption
BRPI0511530A (pt)	2004-05-24	2008-01-02	Procter & Gamble	formas de dosagem de bisfosfonatos
CZ296937B6 (cs) *	2004-09-02	2006-07-12	Zentiva, A. S	Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
WO2006050122A1 (en) *	2004-10-29	2006-05-11	Sandoz Ag	Processes for preparing glatiramer
US20060134190A1 (en) *	2004-12-16	2006-06-22	Banner Pharmacaps Inc.	Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) *	2004-12-28	2006-10-11	Zentiva, A. S.	Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) *	2005-10-20	2011-08-23	Dr. Reddy's Laboratories Limited	Process for preparing bisphosphonic acids
AR058168A1 (es) *	2005-11-07	2008-01-23	Merck & Co Inc	Sintesis del alendronato de sodio trihidratado
CN101568544B (zh) *	2006-10-27	2016-10-26	西格诺药品有限公司	包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
ES2392890T3 (es) *	2006-11-22	2012-12-14	Eisai R&D Management Co., Ltd.	Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched bazedoxifene
US20090118238A1 (en) *	2007-09-17	2009-05-07	Protia, Llc	Deuterium-enriched alendronate
US20090170815A1 (en) *	2007-12-28	2009-07-02	Roxane Laboratories Incorporated.	Alendronate oral liquid formulations
JP2013510097A (ja) *	2009-11-03	2013-03-21	リウ、リー	タンシノンｉｉａスルホン酸ナトリウム水和物、並びにその調製方法及び使用
EP3578546A1 (de)	2013-11-15	2019-12-11	Akebia Therapeutics Inc.	Feste formen von {[5-(3-chlorophenyl)-3-hydroxypyridin-2-carbonyl]amino}essigsäure, zusammensetzungen und verwendungen davon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3016289A1 (de)	1980-04-28	1981-10-29	Henkel KGaA, 4000 Düsseldorf	Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) *	1982-04-15	1989-01-27	Gentili Ist Spa	Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) *	1984-08-06	1987-01-27	Ciba-Geigy Corporation	Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de)	1984-09-21	1986-04-03	Henkel KGaA, 4000 Düsseldorf	4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it)	1984-10-29	1988-11-16	Gentili Ist Spa	Procedimento per la preparazione di acidi difosfonici
US4711800A (en) *	1985-06-06	1987-12-08	Divincenzo Maureen	Needlecraft with metallic substrate
US4922007A (en) *	1989-06-09	1990-05-01	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) *	1990-06-20	1991-05-28	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) *	1990-09-18	1992-10-27	Merck & Co., Inc.	Process for preparing an antihypercalcemic agent
US5039819A (en)	1990-09-18	1991-08-13	Merck & Co., Inc.	Diphosphonate intermediate for preparing an antihypercalcemic agent
AU5886096A (en) *	1995-06-06	1996-12-24	Merck & Co., Inc.	Anhydrous alendronate monosodium salt formulations
AU6148396A (en)	1995-06-06	1996-12-24	Merck & Co., Inc.	Disodium alendronate formulations

1999
- 1999-08-27 SK SK248-2001A patent/SK2482001A3/sk unknown
- 1999-08-27 DK DK99944004T patent/DK1107974T3/da active
- 1999-08-27 RO ROA200100219A patent/RO122854B1/ro unknown
- 1999-08-27 SI SI9920070A patent/SI20581B/sl not_active IP Right Cessation
- 1999-08-27 ES ES99944004T patent/ES2270613T3/es not_active Expired - Lifetime
- 1999-08-27 KR KR1020077004456A patent/KR20070034132A/ko not_active Ceased
- 1999-08-27 AU AU56988/99A patent/AU5698899A/en not_active Abandoned
- 1999-08-27 EA EA200100184A patent/EA002739B1/ru not_active IP Right Cessation
- 1999-08-27 CZ CZ2001629A patent/CZ2001629A3/cs unknown
- 1999-08-27 US US09/384,145 patent/US6281381B1/en not_active Expired - Fee Related
- 1999-08-27 EE EEP200100126A patent/EE04552B1/xx not_active IP Right Cessation
- 1999-08-27 BR BR9913472-1A patent/BR9913472A/pt not_active Application Discontinuation
- 1999-08-27 CA CA002341459A patent/CA2341459A1/en not_active Abandoned
- 1999-08-27 PL PL99346347A patent/PL346347A1/xx not_active Application Discontinuation
- 1999-08-27 AT AT99944004T patent/ATE334993T1/de not_active IP Right Cessation
- 1999-08-27 WO PCT/US1999/019838 patent/WO2000012517A1/en not_active Ceased
- 1999-08-27 IL IL14142399A patent/IL141423A/xx not_active IP Right Cessation
- 1999-08-27 KR KR1020017002535A patent/KR20010079701A/ko not_active Ceased
- 1999-08-27 NZ NZ510682A patent/NZ510682A/en not_active IP Right Cessation
- 1999-08-27 PT PT99944004T patent/PT1107974E/pt unknown
- 1999-08-27 HU HU0203078A patent/HUP0203078A3/hu unknown
- 1999-08-27 DE DE69932620T patent/DE69932620T2/de not_active Expired - Fee Related
- 1999-08-27 JP JP2000567539A patent/JP2002523514A/ja not_active Withdrawn
- 1999-08-27 HR HR20010129A patent/HRP20010129A2/hr not_active Application Discontinuation
- 1999-08-27 YU YU14701A patent/YU14701A/sh unknown
- 1999-08-27 EP EP99944004A patent/EP1107974B1/de not_active Expired - Lifetime
2001
- 2001-02-26 NO NO20010957A patent/NO20010957L/no not_active Application Discontinuation
- 2001-02-26 IS IS5864A patent/IS5864A/is unknown
- 2001-02-26 BG BG105292A patent/BG65329B1/bg unknown
- 2001-02-26 LT LT2001016A patent/LT4888B/lt not_active IP Right Cessation
- 2001-04-05 LV LVP-01-26A patent/LV12720B/en unknown
- 2001-07-03 US US09/898,756 patent/US6696601B2/en not_active Expired - Fee Related
2009
- 2009-02-18 JP JP2009035788A patent/JP2009143955A/ja active Pending

Also Published As

Publication number	Publication date
LV12720B (en)	2002-02-20
KR20010079701A (ko)	2001-08-22
YU14701A (sh)	2003-01-31
EP1107974B1 (de)	2006-08-02
US6281381B1 (en)	2001-08-28
US6696601B2 (en)	2004-02-24
EP1107974A1 (de)	2001-06-20
BR9913472A (pt)	2002-03-05
RO122854B1 (ro)	2010-03-30
IS5864A (is)	2001-02-26
ES2270613T3 (es)	2007-04-01
IL141423A0 (en)	2002-03-10
DE69932620D1 (de)	2006-09-14
HRP20010129A2 (en)	2005-04-30
CA2341459A1 (en)	2000-03-09
LT2001016A (en)	2001-10-25
LT4888B (lt)	2002-02-25
EE200100126A (et)	2002-06-17
DK1107974T3 (da)	2006-10-30
NO20010957L (no)	2001-04-26
NO20010957D0 (no)	2001-02-26
JP2009143955A (ja)	2009-07-02
EA002739B1 (ru)	2002-08-29
JP2002523514A (ja)	2002-07-30
EE04552B1 (et)	2005-10-17
WO2000012517A9 (en)	2000-07-13
US20030065214A1 (en)	2003-04-03
SI20581A (sl)	2001-12-31
SI20581B (sl)	2008-06-30
HUP0203078A3 (en)	2005-01-28
EP1107974A4 (de)	2001-09-26
PT1107974E (pt)	2006-10-31
HUP0203078A2 (hu)	2003-01-28
KR20070034132A (ko)	2007-03-27
EA200100184A1 (ru)	2001-10-22
NZ510682A (en)	2003-09-26
AU5698899A (en)	2000-03-21
BG105292A (en)	2001-12-29
IL141423A (en)	2005-09-25
DE69932620T2 (de)	2006-12-14
PL346347A1 (en)	2002-02-11
LV12720A (lv)	2001-09-20
SK2482001A3 (en)	2002-01-07
WO2000012517A1 (en)	2000-03-09
BG65329B1 (bg)	2008-02-29
CZ2001629A3 (cs)	2001-08-15

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1107974

Country of ref document: EP

2010-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69932620D1 (de)	2006-09-14	Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
CA2337991A1 (en)	2000-01-27	Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
ZA953469B (en)	1996-01-17	New compound
NO995006D0 (no)	1999-10-14	Nye forbindelser
ATE186305T1 (de)	1999-11-15	Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
ATE216576T1 (de)	2002-05-15	Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen
CA2415354A1 (en)	2002-01-31	Phospholipid derivatives of valproic acid and mixtures thereof
PT1051159E (pt)	2002-09-30	Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
BG105275A (en)	2001-11-30	Tan-1057 derivatives
HU9602072D0 (en)	1996-09-30	Substituted cinnamic acid guanidines, process for producing them, and pharmaceutical compositions containing them
SI0748795T1 (en)	2001-02-28	Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them
HU9800512D0 (en)	1998-04-28	Salts of bismuthum and antibiotica of the moenomycin group, process for producing them, their use and pharmaceutical compositions containing them
HUP0103712A2 (hu)	2002-05-29	Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
DE59807096D1 (de)	2003-03-06	Verfahren zur herstellung von fludarabin-phosphat-lithium-, natrium-, kalium-, calcium- und magnesium-salzen, reinigungsverfahren zur herstellung von fludarabin-phosphat und fludarabin-phosphat mit mindestens 99,5 %iger reinheit
FR2665374B1 (fr)	1992-12-04	Microcapsules a paroi mixte d'atelocollagene et de polyholosides coagulee par un cation bivalent et procede de fabrication de ces microcapsules et des compositions cosmetiques ou pharmaceutiques ou alimentaires en contenant.
ATE205473T1 (de)	2001-09-15	Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
ES2137665T3 (es)	1999-12-16	Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
DE59606000D1 (de)	2000-11-23	Verfahren zur Herstellung von 2-Phosphonobutan-1,2,4-tricarbonsäure und ihrer Alkalimetallsalze
EP1702924A3 (de)	2007-07-18	Hydratformen des Natriumsalzes von Alendronat, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen
ZA944317B (en)	1995-12-18	New phosphonosuccinic acid derivatives processes for the preparation thereof and pharmaceutical compositions containing them
RU2003117876A (ru)	2004-12-27	Фармацевтическая композиция для лечения воспалительных процессов в заднем отрезке глаза "делипос"
MXPA04000953A (es)	2004-04-20	Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
ZA200104651B (en)	2002-08-28	Use of substituted 4-biarylbutyric 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases.